Precision oncology: separating the wheat from the chaff

Area of Science:

• Oncology
• Genomics
• Clinical Practice

Background:

• Precision oncology, driven by next-generation sequencing (NGS) tests, is increasingly integrated into clinical practice.
• The large-scale impact of NGS-guided precision oncology on patient outcomes requires further evaluation.
• Understanding the challenges in implementing and interpreting genomic data is crucial for its effective use.

Purpose of the Study:

• To review the existing literature on the clinical utility and impact of precision oncology using NGS.
• To identify limitations hindering the widespread implementation of NGS in clinical settings.
• To discuss challenges in genomic variant interpretation and the function of molecular tumor boards.

Main Methods:

• Comprehensive literature review of studies evaluating precision oncology and NGS.
• Analysis of data on implementation barriers, including genomic variant interpretation.
• Examination of the role and effectiveness of molecular tumor boards.

Main Results:

• Precision oncology is expanding, but its broad impact on patient outcomes remains uncertain.
• Significant bottlenecks exist in genomic variant interpretation and data analysis.
• Molecular tumor boards play a key role in integrating genomic information into treatment decisions.

Conclusions:

• While precision oncology shows promise, challenges in NGS implementation and interpretation need addressing.
• Further research is needed to establish the large-scale clinical and economic benefits of NGS.
• Optimizing molecular tumor board function is essential for maximizing the potential of precision oncology.